Hereditary Elliptocytosis

Article written and reviewed by Dr Luca Moretti

Hereditary elliptocytosis is a congenital red-cell membrane disorder characterized by elliptical or oval red blood cells in peripheral blood. It is caused by qualitative or quantitative abnormalities of red-cell cytoskeletal proteins responsible for red-cell stability and deformability. The clinical spectrum is broad: most affected individuals are asymptomatic or have mild compensated hemolysis, whereas a minority develop chronic hemolytic anemia of variable severity, occasionally complicated by episodes of acute hemolysis or aplastic crises.

Hereditary elliptocytosis occurs worldwide, with higher prevalence in African, Mediterranean and Southeast Asian populations. Diagnosis is based on recognition of elliptical red blood cells on the peripheral smear, laboratory studies and, in selected cases, identification of specific red-cell protein variants through genetic testing. Management is generally conservative in mild forms, while severe forms may require splenectomy and supportive therapy.

The effect on quality of life is generally modest, but severe forms may cause hematologic and biliary complications requiring multidisciplinary follow-up and careful prevention of hemolytic crises and post-splenectomy infections.

Etiology

Hereditary elliptocytosis is caused by variants in genes encoding red-cell cytoskeletal proteins, particularly alpha spectrin (SPTA1), beta spectrin (SPTB), protein 4.1R (EPB41) and, less commonly, glycophorin C. These proteins are essential for maintaining the biconcave shape and mechanical integrity of red blood cells, especially during passage through capillaries and splenic sinusoids.

Inheritance is typically autosomal dominant, although autosomal recessive forms associated with more severe phenotypes have been described, particularly with alpha-spectrin variants or combinations of multiple defects. These variants reduce longitudinal stability of the red-cell membrane and produce elliptical or oval red blood cells.

The most common molecular defect involves alpha spectrin, affected in approximately 65% of cases, followed by beta spectrin and protein 4.1R. Structural abnormalities reduce spectrin’s ability to form its normal elastic network and promote permanent longitudinal deformation of the cell.

Disease severity depends on the type of variant and degree of functional impairment of the affected proteins. Homozygous or compound forms are generally associated with more severe phenotypes and chronic hemolytic anemia, whereas heterozygous individuals almost always have subclinical or asymptomatic disease.

Risk Factors and Prevention

Hereditary elliptocytosis is genetically determined; however, several factors can modify clinical severity or promote complications:

• Positive family history: elliptocytosis in one or both parents increases the risk of clinically manifest disease and, when severe variants are inherited from both parental lines, of severe phenotypes
• Compound heterozygosity: two different pathogenic variants in the same gene, one on each allele, are associated with more severe disease
• Folate deficiency or other conditions of increased erythropoietic demand may aggravate anemia but do not cause an aplastic crisis
• Viral infections, particularly Parvovirus B19, may cause aplastic crises with acute worsening of anemia

Prevention of complications relies on timely diagnosis, folic acid supplementation in symptomatic patients, prevention of infections, and education of patients and families about warning signs and crisis management.

Pathogenesis and Pathophysiology

The pathogenesis of hereditary elliptocytosis results from loss of longitudinal stability of the red-cell membrane cytoskeleton due to defects in spectrin or accessory proteins. Normally, spectrin forms a flexible, resilient network that maintains the biconcave shape and allows transient deformation during passage through microvessels.

In hereditary elliptocytosis, reduced spectrin self-association or impaired interaction with other membrane proteins causes loss of elasticity and an irreversible tendency toward cell elongation. Red blood cells acquire an elliptical or oval morphology and become progressively less deformable.

During transit through splenic sinusoids, elliptical cells undergo repeated mechanical injury, with microfragmentation and shortened red-cell survival through extravascular hemolysis, accompanied by compensatory bone marrow erythropoiesis. The degree of hemolysis depends on the balance between red-cell loss and marrow compensation, explaining the broad clinical variability.

In severe forms, risks of chronic anemia, jaundice and pigment gallstones increase, whereas mild variants may remain completely asymptomatic throughout life.

Clinical Presentation

The clinical presentation of hereditary elliptocytosis is extremely heterogeneous, ranging from completely asymptomatic disease to chronic hemolytic anemia with complications. Most affected individuals have a mild or subclinical form discovered incidentally during routine hematologic testing or family screening. Severe forms, generally associated with homozygous or compound variants, present in childhood with chronic hemolytic anemia, intermittent jaundice, splenomegaly and sometimes episodes of acute hemolytic or aplastic crises.

The most common clinical manifestations include:

• Mucocutaneous pallor from chronic anemia of variable severity
• Mild to moderate jaundice from indirect hyperbilirubinemia
• Splenomegaly usually modest but more pronounced in severe forms
• Pigment gallstones especially in patients with marked hemolysis
• Episodes of hemolytic crisis during infections and aplastic crises due to Parvovirus B19

Mild forms may be asymptomatic or cause only modest compensated anemia, whereas severe forms may cause growth delay, marked fatigue and recurrent transfusion requirements.

The aplastic crisis is a rare but serious complication, causing rapid worsening of anemia through transient arrest of erythropoiesis, often due to Parvovirus B19 infection, with risk of acute hemodynamic decompensation, especially in children and patients with limited erythropoietic reserve.

In nonsplenectomized patients, progressive splenic enlargement may cause hypersplenism with reductions in other blood cell lines such as platelets and leukocytes and increased risk of infection and bleeding.

Overall, prognosis is favorable in mild hereditary elliptocytosis, while in severe variants quality of life and growth depend on early diagnosis, crisis management, and prevention of biliary and infectious complications.

Diagnostic Evaluation

The diagnosis of hereditary elliptocytosis is based on a combination of clinical, laboratory and morphological data, with genetic confirmation in selected cases. The diagnostic process aims to distinguish hereditary elliptocytosis from other causes of hemolytic anemia and acquired forms of ovalocytosis.

First-line diagnostic work-up:

• Complete blood count: shows generally normocytic anemia with compensatory reticulocytosis in symptomatic forms. Platelets and leukocytes are generally normal unless hypersplenism is present.
• Peripheral blood smear: the cornerstone of diagnosis, showing an increased proportion of elliptical or oval red blood cells. The percentage varies widely and should be interpreted with overall morphology, family history and clinical and laboratory findings. In severe forms, nearly all red blood cells may be elliptical.
• Markers of hemolysis: increased indirect bilirubin, elevated LDH, reduced haptoglobin and persistent reticulocytosis in the absence of an aplastic crisis.
• Direct antiglobulin test: generally negative; positivity suggests an immune mechanism, while a negative result does not completely exclude rare DAT-negative AIHA.

Specific second-line tests:

• Osmotic fragility test: usually normal or only mildly increased; the typical finding is the morphology of elliptocytes rather than marked osmotic fragility.
• Flow cytometry (EMA binding test): less sensitive than in hereditary spherocytosis but may show reduced binding in severe spectrin defects.
• Red-cell membrane protein analysis: electrophoresis or molecular techniques to identify the deficient or altered protein and are useful in severe or atypical forms or for genetic purposes.
• Genetic testing: reserved for complex family histories, severe phenotypes, or genetic or prenatal counseling.

Hereditary elliptocytosis is strongly suggested by a significant proportion of elliptocytes on the peripheral smear together with the clinical and family context; chronic hemolysis may be absent in common asymptomatic forms.

Differential diagnosis: The main differential diagnoses include:

• Autoimmune hemolytic anemia: may show spherocytes and a generally positive direct antiglobulin test, although rare DAT-negative forms exist; the clinical context and immunohematologic testing complete the differential diagnosis
• Stomatocytosis, spherocytosis and other hereditary red-cell membrane disorders: distinguished by red-cell morphology and specific laboratory tests
• Acquired elliptocytosis/ovalocytosis: may be seen with iron deficiency, thalassemia, burns, myelodysplasia and other acquired conditions; reversibility depends on the underlying cause and is not a constant feature.

Correct identification allows targeted follow-up and prevention of associated complications.

Early and accurate diagnosis allows preventive strategies, education of patients and families, and timely treatment planning in severe forms.

Treatment and Prognosis

Treatment of hereditary elliptocytosis is individualized according to clinical severity, symptomatic anemia and complication risk. Most patients have mild or asymptomatic disease and require no specific treatment beyond periodic follow-up. In moderate to severe forms, goals are to reduce anemia severity, prevent hemolytic crises, ensure adequate growth and development in children, and minimize biliary and infectious complications.

Supportive treatment:

• Folic acid supplementation: indicated in symptomatic patients to support compensatory erythropoiesis and prevent folate deficiency; it does not prevent Parvovirus B19 aplastic crises.
• Red-cell transfusions: reserved for severe forms or aplastic crises, particularly in young children or patients with acute decompensation.
• Treatment of biliary complications: cholecystectomy should be considered for symptomatic gallstones, cholecystitis or pancreatitis.
• Management of hemolytic and aplastic crises: hematologic monitoring, treatment of infections and timely transfusion support.

Regular clinical and laboratory follow-up is essential for early detection of complications, assessment of growth in children and monitoring of splenic function.

Splenectomy: Splenectomy is the treatment of choice in severe forms with symptomatic anemia, recurrent transfusion requirements or complications related to hypersplenism. Preferably performed after 5 years of age, it markedly improves anemia and red-cell survival but increases the risk of serious infection with encapsulated bacteria such as Streptococcus pneumoniae, Neisseria meningitidis, Haemophilus influenzae and thromboembolic complications. Specific vaccination is essential and prolonged antibiotic prophylaxis is required after surgery in children.

Emerging therapeutic approaches: Although treatment remains mainly supportive, pharmacologic and molecular approaches aimed at correcting spectrin defects or improving red-cell deformability are under study. No specific gene or pharmacologic therapy is currently available in clinical practice.

Prognosis: Prognosis is generally excellent in mild and moderate hereditary elliptocytosis, with normal life expectancy and no major limitations. In severe forms, splenectomy and appropriate management of complications can provide good quality of life provided all measures to prevent infectious and thrombotic risk are implemented. Major adverse prognostic factors include aplastic crises, biliary complications and severe post-splenectomy infections.

Prevention of complications relies on early diagnosis, education of patients and families, vaccination, folate supplementation and regular clinical monitoring.

Complications

The complications of hereditary elliptocytosis are similar to those seen in other hereditary red-cell membrane disorders but are generally less frequent than in hereditary spherocytosis. In severe disease, however, they can cause substantial morbidity and require specific treatment.

Hematologic complications:

• Acute aplastic crises: especially secondary to Parvovirus B19 infection, with abrupt reduction in red-cell production and risk of severe anemia and decompensation.
• Acute hemolytic crises: mainly associated with infections, causing transient worsening of anemia and jaundice.

Biliary complications:

• Pigment gallstones especially in patients with marked hemolysis, with risk of colic, cholecystitis and pancreatitis.
• Biliary tract infections may also occur in severe pediatric cases.

Infectious complications: After splenectomy, the risk of severe infection from encapsulated bacteria increases, requiring vaccination and, in children, long-term antibiotic prophylaxis after surgery.

Thromboembolic complications: Thrombotic risk increases after splenectomy, especially in patients with other risk factors or a positive family history.

Nutritional and growth complications: Children with severe disease and chronically poorly compensated anemia may develop growth delay. Malnutrition and vitamin deficiencies are not intrinsic complications and should be assessed separately.

Overall, management of complications requires multidisciplinary follow-up, education about warning signs and a proactive approach to preventing infections and hemolytic crises.

Bibliography
1. Gallagher PG. Red cell membrane disorders. Hematology Am Soc Hematol Educ Program. 2005:13–18.
2. Delaunay J. The molecular basis of hereditary red cell membrane disorders. Blood Rev. 2007;21(1):1–20.
3. Iolascon A, Andolfo I, Russo R. Advances in understanding the pathogenesis of red cell membrane disorders. Br J Haematol. 2019;187(1):13–24.
4. King MJ, Zanella A. Hereditary red cell membrane disorders and laboratory diagnostic testing. Int J Lab Hematol. 2013;35(3):237–243.
5. Da Costa L, Galimand J, Fenneteau O, Mohandas N. Hereditary spherocytosis, elliptocytosis, and other red cell membrane disorders. Blood Rev. 2013;27(4):167–178.
6. Lux SE. Disorders of the Red Cell Membrane. In: Orkin SH, Fisher DE, Ginsburg D, Look AT, Lux SE, Nathan DG, eds. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. 8th ed. Philadelphia: Elsevier; 2015:515–579.e21.
7. Gallagher PG. Hereditary elliptocytosis: spectrin and protein 4.1R. Semin Hematol. 2004;41(2):142–164.
8. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet. 2008;372(9647):1411–1426.
9. Bolton-Maggs PH, Langer JC, Iolascon A, et al. Guidelines for the diagnosis and management of hereditary spherocytosis—2011 update. Br J Haematol. 2012;156(1):37–49.
10. Bianchi P, Fermo E, Vercellati C, et al. Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologica. 2012;97(4):516–523.
11. Narla J, Mohandas N. Red cell membrane disorders. Int J Lab Hematol. 2017;39 Suppl 1:47–52.
12. Kalfa TA. Diagnosis and clinical management of red cell membrane disorders. Hematology Am Soc Hematol Educ Program. 2021;2021(1):331–340.